Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophos…
Biotechnology
GB, London [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Roivant Sciences Ltd.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -1.3800 | -1.180 | 55 | 52 | -924 | -980 | -1,499 | -31 | -1,211 | -52 | 775 | 478 |
| 2023 | -1.7300 | -1.588 | 61 | 52 | -1,230 | -1,319 | -1,107 | -31 | -1,077 | -52 | 600 | 472 |
| 2024 | - | 5.221 | - | 181 | - | 4,736 | - | -109 | - | -181 | - | 1,643 |
| 2025 | - | -0.740 | - | 185 | - | -514 | - | -111 | - | -185 | - | 1,679 |
| 2026 | - | -0.705 | - | 185 | - | 3.F4X/td> | - | 3.F41/td> | - | 3.F41 | - | 3.F41 |
| 2027 | - | -0.906 | - | 386 | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2028 | - | -0.360 | - | 1,135 | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2029 | - | 0.472 | - | 2,106 | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Overweight
Prev. Grade
Overweight
Nov. 21, 2024
Overweight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-44.332% $5.24 · MISS
Nov. 6, 2024Price Then
$11.66
Price Target
$17.06
Price Now
$11.82